Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 9:52 p.m.

    📋 Karuna Therapeutics, Inc. (KRTX) - Clinical Trial Update

    Filing Date: 2022-08-08

    Accepted: 2022-08-08 06:43:14

    Event Type: Clinical Trial Update

    Event Details:

    Karuna Therapeutics (was acquised by Bristol Myers Squibb (NYSE: BMY) on 18/03/2024) (KRTX) Announces Clinical Trial Update Karuna Therapeutics (was acquised by Bristol Myers Squibb (NYSE: BMY) on 18/03/2024) (KRTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: reduction, KarXT
    • Diseases/Conditions: Schizophrenia Trial met primary endpoint
    • Clinical Stage: Phase 3
    • Collaboration: PANSS
    • Updated Timeline: mid-2023
      • expected in mid-2023
      • expected in the first quarter of 2023

    🔬 Clinical Development Pipeline (Karuna Therapeutics, Inc.):

    Product Type Development Stage Therapeutic Area Source
    KarXT DRUG Phase PHASE3 Psychosis Associated With Alzheimer's Disease ClinicalTrials.gov
    Xanomeline/ Trospium Chloride DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    KarX-EC DRUG Phase PHASE3 Psychosis Associated With Alzheimer's Disease ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Karuna Therapeutics (was acquised by Bristol Myers Squibb (NYSE: BMY) on 18/03/2024)
    • CIK: 0001771917
    • Ticker Symbol: KRTX
    • Period End Date: 2022-08-08
    • Document Type: 8-K

Search

News categories